Evolent Health (NYSE:EVH) Posts Quarterly Earnings Results, Misses Expectations By $0.35 EPS

Evolent Health (NYSE:EVH) released its earnings results on Thursday. The technology company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.38 by ($0.35), Zacks reports. Evolent Health had a negative net margin of 2.93% and a positive return on equity of 6.30%.

Evolent Health Trading Up 1.8 %

EVH stock traded up $0.19 during midday trading on Thursday, hitting $10.71. 2,623,019 shares of the company’s stock were exchanged, compared to its average volume of 2,149,710. The stock’s fifty day moving average price is $10.79 and its 200-day moving average price is $18.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. The company has a market cap of $1.25 billion, a PE ratio of -11.77 and a beta of 1.45. Evolent Health has a one year low of $9.45 and a one year high of $35.00.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. BTIG Research lowered their target price on Evolent Health from $36.00 to $29.00 and set a “buy” rating for the company in a research note on Tuesday, December 3rd. JMP Securities reissued a “market outperform” rating and issued a $12.00 target price on shares of Evolent Health in a research note on Friday, February 14th. Barclays lowered their target price on Evolent Health from $39.00 to $19.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. Stephens decreased their price objective on Evolent Health from $16.00 to $12.00 and set an “equal weight” rating for the company in a research note on Tuesday, January 21st. Finally, Royal Bank of Canada decreased their price objective on Evolent Health from $20.00 to $17.00 and set an “outperform” rating for the company in a research note on Tuesday, January 14th. One analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $17.92.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.